A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression
Seagen Inc.
Seagen Inc.
Dana-Farber Cancer Institute
Chengdu Zenitar Biomedical Technology Co., Ltd
Ohio State University Comprehensive Cancer Center
Fudan University
National Institutes of Health Clinical Center (CC)
Dizal Pharmaceuticals
Columbia University
Ruijin Hospital
Daiichi Sankyo
UNC Lineberger Comprehensive Cancer Center
National Cancer Centre, Singapore
Affimed GmbH
The Lymphoma Academic Research Organisation
The Lymphoma Academic Research Organisation
Ruijin Hospital
Dizal Pharmaceuticals
Sun Yat-sen University
Institute of Hematology & Blood Diseases Hospital, China
Seoul National University Hospital
Yale University
Great Novel Therapeutics Biotech & Medicals Corporation
The First Affiliated Hospital of Xiamen University
Institute of Hematology & Blood Diseases Hospital, China
Evopoint Biosciences Inc.
Affimed GmbH
BeiGene
HUYABIO International, LLC.
The First Hospital of Jilin University
AstraZeneca
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Kura Oncology, Inc.
Kyowa Kirin Co., Ltd.
Tianjin Medical University Cancer Institute and Hospital
Kyowa Kirin Co., Ltd.
University of Michigan Rogel Cancer Center
Solasia Pharma K.K.
University of Nebraska
Seagen Inc.
University of Nebraska
Henan Cancer Hospital
Weill Medical College of Cornell University
Huazhong University of Science and Technology
Ruijin Hospital
Sorrento Therapeutics, Inc.
Karyopharm Therapeutics Inc
Rhizen Pharmaceuticals SA
Second Affiliated Hospital, School of Medicine, Zhejiang University
Mayo Clinic
The First Affiliated Hospital with Nanjing Medical University